GlassScriptPhysician profile
Michael J Seidman
NPI 1982728283
$37,263.24
in general payments reported to CMS, 2019-2025
43 companies · $670 in 2025
The $670 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,423 · 2020: $6,111 · 2021: $4,886 · 2022: $7,701 · 2023: $9,150 · 2024: $5,322 · 2025: $670.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $15K · Food and Beverage: $481 · Education: $12.42.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $14,648.00 |
| Food and Beverage | $481.07 |
| Education | $12.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $14,686.87 | 2019-2023 | Lunsumio, Venclexta, Polivy |
| Glaxosmithkline, LLC. | $7,125.14 | 2020-2025 | Ojjaara, Blenrep, Jemperli |
| E.R. Squibb & Sons, L.L.C. | $2,507.19 | 2019-2021 | |
| Celgene Corporation | $1,757.69 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $1,669.29 | 2019 | |
| Beigene USA, INC. | $1,650.00 | 2023 | Brukinsa |
| Janssen Scientific Affairs, LLC | $1,515.00 | 2022 | |
| Exelixis INC. | $1,470.00 | 2021 | |
| Janssen Biotech, INC. | $1,441.04 | 2019-2025 | Tecvayli, Talvey |
| Foundation Medicine, INC. | $1,050.00 | 2019-2020 | |
| Tersera Therapeutics LLC | $393.00 | 2025 | Zoladex |
| Novocure Gmbh | $250.00 | 2022 | |
| Amgen INC. | $170.73 | 2019-2020 | |
| Astellas Pharma US INC | $145.07 | 2019-2025 | Xospata, Vyloy, Xtandi |
| Astrazeneca Pharmaceuticals LP | $123.05 | 2019-2020 |
Show all 43 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Seidman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.